# Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression"

Chunru Wang

Potential competing interests: No potential competing interests to declare.

This article proposed a theory that beta cells regenerate in type 1 diabetes through the synergistic approach of dual GLP-1 agonist with degludec basal insulin, it is an important research since daily basal-bolus insulin is the primary treatment option. However, I think the manuscript lacks reasonable and logical writing, it need much more improvement.

1. I think lots of the descriptions in the whole manuscript are lack of logic. It should be improved, such as the first and second sentences in Introduction, and so on.

2. This manuscript presents that “the information provided suggests a comprehensive and interconnected perspective on the potential treatment of type 1diabetes through the synergistic approach of dual GLP-1 agonist with degludec basal insulin”, is this synergistic approach of dual GLP-1 agonist with degludec basal insulin available in the present research? The evidence should be provided.

3. The second part is “Interpretation and Commentary on the Manuscript "Semaglutide in Early Type 1 Diabetes" by Paresh Dandona, M.D., Ph.D., and Ajay Chaudhur, M.D., published in The New England Journal of Medicine on September 7, 2023.” But the comments such as “direct reprogramming of liver cells into insulin-producing cells” are not associated with above published article, is that suitable?

4. More references need to be added to support the comments and descriptions in this manuscript, such as “Additionally, previous studies have suggested that pancreatic exocrine duct cells have the potential to differentiate into insulin-producing beta cells during embryogenesis but not after birth.”, “The direct reprogramming of liver cells into insulin-producing cells offers another approach for cell replacement therapy.” and so on.